1. Home
  2. FATE vs OCCI Comparison

FATE vs OCCI Comparison

Compare FATE & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • OCCI
  • Stock Information
  • Founded
  • FATE 2007
  • OCCI N/A
  • Country
  • FATE United States
  • OCCI United States
  • Employees
  • FATE N/A
  • OCCI N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • OCCI Trusts Except Educational Religious and Charitable
  • Sector
  • FATE Health Care
  • OCCI Finance
  • Exchange
  • FATE Nasdaq
  • OCCI Nasdaq
  • Market Cap
  • FATE 177.7M
  • OCCI 160.5M
  • IPO Year
  • FATE 2013
  • OCCI N/A
  • Fundamental
  • Price
  • FATE $1.14
  • OCCI $6.28
  • Analyst Decision
  • FATE Hold
  • OCCI
  • Analyst Count
  • FATE 7
  • OCCI 0
  • Target Price
  • FATE $3.83
  • OCCI N/A
  • AVG Volume (30 Days)
  • FATE 1.7M
  • OCCI 115.8K
  • Earning Date
  • FATE 08-12-2025
  • OCCI 12-11-2023
  • Dividend Yield
  • FATE N/A
  • OCCI 24.32%
  • EPS Growth
  • FATE N/A
  • OCCI N/A
  • EPS
  • FATE N/A
  • OCCI N/A
  • Revenue
  • FATE $13,335,000.00
  • OCCI N/A
  • Revenue This Year
  • FATE N/A
  • OCCI N/A
  • Revenue Next Year
  • FATE N/A
  • OCCI $10.19
  • P/E Ratio
  • FATE N/A
  • OCCI N/A
  • Revenue Growth
  • FATE 105.85
  • OCCI N/A
  • 52 Week Low
  • FATE $0.66
  • OCCI $5.47
  • 52 Week High
  • FATE $5.92
  • OCCI $10.15
  • Technical
  • Relative Strength Index (RSI)
  • FATE 46.69
  • OCCI 53.05
  • Support Level
  • FATE $1.05
  • OCCI $6.21
  • Resistance Level
  • FATE $1.18
  • OCCI $6.30
  • Average True Range (ATR)
  • FATE 0.08
  • OCCI 0.08
  • MACD
  • FATE -0.00
  • OCCI 0.02
  • Stochastic Oscillator
  • FATE 54.76
  • OCCI 94.05

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About OCCI OFS Credit Company Inc.

OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation primarily through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.

Share on Social Networks: